Biomarkers and Efficacy: Not (Yet?) a Perfect Union
Scientists at AAIC debated discrepant results, updated a model of the biomarker-efficacy relationship, and debuted the CenTauR scale for tau PET.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
What Factors Make Amyloid Immunotherapy Successful?
At AAIC 2023, scientists tied clinical success to drug exposure, speed of plaque clearance, amyloid negativity.
With Age, Microglia Pump cGAS, Revving Harmful Inflammation
DNA from leaky mitochondria unleash the cGAS-STING cascade, triggering interferon responses in the brain.
In Frontotemporal Lobar Dementia, TDP-43 Snaps into a Chevron Shape
A section of the protein folds on itself to form five layers. Three V-shaped layers cradle each other. This differs from the double-spiral fold in people with FTD/ALS.
Revised Again: Alzheimer's Diagnostic Criteria Get Another Makeover
The newly proposed scheme uses only amyloid and tau for diagnosis and staging. It establishes parallel tracks for fluid or imaging markers, and recognizes a clinical stage zero.
Finally, a Diagnostic Marker for Lewy Body Disease?
α-Synuclein seed amplification assays identify people with LBD. They may outperform clinical diagnosis, and hint that dementia with Lewy bodies might be overdiagnosed.
Does One Copy of the Christchurch ApoE Variant Slow Alzheimer’s?
Twelve people heterozygous for this protective variant were still sharp seven years after their expected age of AD onset. One had fewer tangles than expected.
Organization of Aβ Plaques and Tau Tangles Illuminated in AD Brain
Plaques comprise different-sized fibrils and cell membrane components, while tangles have distinct fibril structures segregated into intra- and extracellular compartments.
Wanted: Fluid Biomarkers for CAA, ARIA
The ability to quickly detect cerebral amyloid angiopathy and ARIA would make amyloid immunotherapy safer, but research in this area is just beginning.
Is ARIA an Inflammatory Reaction to Vascular Amyloid?
Scientists at AAIC said ARIA-E resembles inflammation related to cerebral amyloid angiopathy. The prime suspect? The complement cascade.
Spying on α-Synuclein Inclusions: PET Tracers Inch Closer to Success
A crop of new PET tracers that bind α-synuclein aggregates shows promise in tissue samples and in animal models. Will they prove potent enough for brain imaging?
Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD
First data from the Longitudinal Early-Onset Alzheimer’s Disease Study hints at what might cause this type of AD and how it unfolds.
Could Inhibiting a Liver Enzyme Ameliorate Alzheimer’s Pathology in the Brain?
In mice, curbing a hepatic hydrolase boosted protective epoxy fatty acids in the brain, which stimulated microglia to clear amyloid.
CSF MTBR-tau-243 Tracks Tangles, Plummets in Response to Antibody
In contrast to phospho-tau species that mirror amyloid, CSF MTBR-tau-243 reflects tau-PET. It fell upon treatment with an antibody against tau’s midsection.
Give BACE Inhibitors a Second Chance?
Between basic researchers and clinicians, momentum is growing to test BACE inhibition again. This time, at low doses.
Current Filters
No filters selected